在分支视网膜静脉封闭后的黄斑胀中的视网膜下液体
Donghyun Jee1, Soyoung Park1, Jin-Woo Kwon2
1Department of Ophthalmology and Visual Science, St. Vincent's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.
Scientific reports
|June 13, 2024
概括
患有黄斑 (ME) 患者分支视网膜静脉封闭 (BRVO) 的视网膜下液体表明,抗血管内皮生长因子 (VEGF) 治疗后疾病活性较高,并导致较大的初始视力敏度增长.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 血管生物学 血管生物学
背景情况:
- 由于分支视网膜静脉封闭 (BRVO) 的二次性斑点 (ME) 可以显著损害视力.
- 亚视网膜液 (SRF) 是ME的常见发现,但其在BRVO的预后影响尚未完全理解.
- 了解SRF的作用可以指导BRVO患者的治疗策略.
研究的目的:
- 为了确定ME和SRF的BRVO患者的特征.
- 为了比较抗血管内皮生长因子 (VEGF) 治疗后与没有SRF的患者之间的临床结果.
- 调查SRF与BRVO诱导的ME疾病活动之间的关联.
主要方法:
- 对 57 个 BRVO 诱导的 ME 的眼睛进行了回顾性分析.
- 分为两组:在诊断时存在或不存在SRF.
- 基线水性特征,眼部/全身特征和抗VEGF治疗后的临床结果的比较.
主要成果:
- 在SRF组显示出更高的基线中央子场厚度 (CST) 和较差的最佳校正视敏度 (BCVA).
- 在SRF组中观察到高水平的互白素-8,VEGF和胎盘生长因子.
- 在SRF组中,在治疗期间观察到更大的CST减少和BCVA改善,最终CST较低,但在12个月后BCVA相似.
- 而SRF组需要更频繁的抗VEGF治疗,并且黄斑缩的发生率更高.
结论:
- 与BRVO相关的ME中的视网膜下液与疾病活性增加有关.
- 存在SRF预测对抗VEGF治疗的初始反应更强,但可能与长期并发症,如黄斑缩有关.
- 需要进一步的研究来优化SRF的BRVO患者的管理策略.
相关概念视频
01:27Diabetic Retinopathy
65
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
65
01:22Cerebral Edema ll: Pathophysiology
31
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
31